From: A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study
Variables | OS | PFS | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Neoadjuvant chemotherapy | 1.367 (0.806–2.319) | 0.246 | 1.136 (0.770–1.678) | 0.521 |
Maintenance therapy with I3C | 0.272 (0.147–0.502) | < 0.0001 | 0.309 (0.202–0.472) | < 0.0001 |
Maintenance therapy with I3C and EGCG | 0.244 (0.150–0.396) | < 0.0001 | 0.241 (0.172–0.339) | < 0.0001 |
PСI (> 25 vs ≤ 25) | 2.829 (1.813–4.415) | < 0.0001 | 2.114 (1.589–2.812) | < 0.0001 |
FIGO stage (IV vs III) | 9.642 (5.963–15.592) | < 0.0001 | 6.953 (4.744–10.190) | < 0.0001 |
Secondary debulking surgery | < 0.0001 (< 0.0001- > 1.0х103) | 0.930 | 1.277 (0.875–1.862) | 0.205 |